Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis

Prospective, Double Blind, Randomized Phase II/III Study to Assess the Safety and Efficacy of SQIN™ on Xerosis in Adults Suffering of Mobility Impairment and/or Complete Paralysis Associated With Chronic Spinal Cord Injury.

In the general population, xerosis is often caused by external factors such as seasonal changes. In that case, the best way to relieve dry skin is to use a standard moisturizer. However, for those suffering of mobility problems due to age or paralysis (e.g., spinal cord injury, multiple sclerosis, Parkinson's, etc), xerosis is often severe and chronic because of the multiple causes (endogenous rather than exogenous ones) underlying such mobility impairment-related skin problems. This study is a double-blind, randomized study with positive control (active comparator) to assess the safety and efficacy of SQIN with CanSATs (Co-Activation of Natural Synergistically Acting Target-receptorS) technology on dry skin in patients suffering of paralysis.

Study Overview

• Status: Completed
• Conditions: Xerosis
• Intervention / Treatment: Other: standard moisturizing cream (Glaxal Base); Other: SQIN

Detailed Description

Xerosis is a medical term for dry skin. When it results in skin that is scaly and itchy, the condition is called pruritus. This occurs when natural moisture is drawn out of the skin. The skin needs moisture to protect itself. The best way to relieve dry skin normally, for those suffering of seasonal dry skin problems, is to use standard moisturizers. However, for those suffering of mobility problems due to age or paralysis (spinal cord injury, multiple sclerosis, Parkinson's, Alzheimer's, muscular dystrophy, amputation, cerebral palsy, or other comparable disorders), xerosis becomes severe and chronic because of the multiple causes (endogenous metabolic problems and dysfunctions rather than exogenous ones). SQIN with CanSATs technology is designed to act upon multiple mechanisms for enhanced protecting, moisturizing, and repairing effects. Based upon preliminary evidence, SQIN with CanSATs technology can thus elicit significantly superior effects compared with standard, commercially available moisturizers.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Quebec City, Quebec, Canada, G1Y2T4
      • Nordic Life Science Pipeline

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Paralyzed due to a spinal cord injury (traumatic or non-traumatic origin)
• Chronically injured (at least 3 months post-injury)
• Paraplegic or tetraplegic
• 18-75 years of age
• Men and women
• French-speaking

Exclusion Criteria:

• Acute or subacute stage (within 1 day and 3 months post-injury)
• Had tumor(s) (malignant or non-malignant) of the skin in the last five (5) years
• Allergic or hypersensitive to any ingredient, investigational or control product
• With psychiatric or mental disorder(s)
• Children (younger than 18 year-old) or elderly (older than 75 year-old)
• Not French-speaking

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Positive Control; Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.	Other: standard moisturizing cream (Glaxal Base)
Experimental: Experimental Cream; Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.	Other: SQIN; Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).; Other Names: SQIN on one side - control cream on other side

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Skin tolerance (Self-assessment of redness or itchiness problems)	Self-assessment of redness or itchiness problems during or after the treatment	14 days
Moisturizing level (Self-assessment (5-level score)	Self-assessment (5-level score) of dry skin conditions before, during and after the treatment	14 days
Elasticity level (Self-assessment (5-level score)	Self-assessment (5-level score) of the elasticity level of the skin before, during and after the treatment	14 days

Collaborators and Investigators

• Sponsor: Nordic Life Science Pipeline Inc.
• Investigators: Study Director: Pierre Guertin, Ph.D., Nordic Life Science Pipeline and Laval University

Study record dates

Study Major Dates

• Study Start: April 1, 2015
• Primary Completion (Actual): June 1, 2015
• Study Completion (Actual): June 1, 2015

Study Registration Dates

• First Submitted: April 17, 2015
• First Submitted That Met QC Criteria: April 28, 2015
• First Posted (Estimate): April 29, 2015

Study Record Updates

• Last Update Posted (Estimate): August 20, 2015
• Last Update Submitted That Met QC Criteria: August 19, 2015
• Last Verified: August 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Paralysis
• Other Study ID Numbers: SQIN-01